These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38869035)

  • 1. CSF and plasma biomarkers in cerebral amyloid angiopathy: A single-center study and a systematic review/meta-analysis.
    Theodorou A; Tsantzali I; Stefanou MI; Sacco S; Katsanos AH; Shoamanesh A; Karapanayiotides T; Koutroulou I; Stamati P; Werring DJ; Cordonnier C; Palaiodimou L; Zompola C; Boviatsis E; Stavrinou L; Frantzeskaki F; Steiner T; Alexandrov AV; Paraskevas GP; Tsivgoulis G
    Eur Stroke J; 2024 Jun; ():23969873241260538. PubMed ID: 38869035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: A meta-analysis.
    Charidimou A; Friedrich JO; Greenberg SM; Viswanathan A
    Neurology; 2018 Feb; 90(9):e754-e762. PubMed ID: 29386280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal Fluid Profile of Tau, Phosphorylated Tau, Aβ42, and Aβ40 in Probable Cerebral Amyloid Angiopathy.
    Grangeon L; Paquet C; Guey S; Zarea A; Martinaud O; Rotharmel M; Maltête D; Quillard-Muraine M; Nicolas G; Charbonnier C; Chabriat H; Wallon D
    J Alzheimers Dis; 2022; 87(2):791-802. PubMed ID: 35367960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy: New Data and Quantitative Meta-Analysis.
    Margraf NG; Jensen-Kondering U; Weiler C; Leypoldt F; Maetzler W; Philippen S; Bartsch T; Flüh C; Röcken C; Möller B; Royl G; Neumann A; Brüggemann N; Roeben B; Schulte C; Bender B; Berg D; Kuhlenbäumer G
    Front Aging Neurosci; 2022; 14():783996. PubMed ID: 35237145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cerebral Amyloid Angiopathy-Related Inflammation.
    Renard D; Wacongne A; Ayrignac X; Charif M; Fourcade G; Azakri S; Le Floch A; Bouly S; Marelli C; Arquizan C; Hirtz C; Gabelle A; Thouvenot E; Lehmann S
    J Alzheimers Dis; 2016; 50(3):759-764. PubMed ID: 26757185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy.
    Banerjee G; Ambler G; Keshavan A; Paterson RW; Foiani MS; Toombs J; Heslegrave A; Dickson JC; Fraioli F; Groves AM; Lunn MP; Fox NC; Zetterberg H; Schott JM; Werring DJ
    J Alzheimers Dis; 2020; 74(4):1189-1201. PubMed ID: 32176643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria.
    Renard D; Castelnovo G; Wacongne A; Le Floch A; Thouvenot E; Mas J; Gabelle A; Labauge P; Lehmann S
    J Neurol; 2012 Nov; 259(11):2429-33. PubMed ID: 22576334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal Fluid Biomarkers and Amyloid-β Elimination from the Brain in Cerebral Amyloid Angiopathy-Related Inflammation.
    Sakai K; Noguchi-Shinohara M; Tanaka H; Ikeda T; Hamaguchi T; Kakita A; Yamada M; Ono K
    J Alzheimers Dis; 2023; 91(3):1173-1183. PubMed ID: 36565118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma amyloid beta 42 is a biomarker for patients with hereditary, but not sporadic, cerebral amyloid angiopathy.
    de Kort AM; Kuiperij HB; Jäkel L; Kersten I; Rasing I; van Etten ES; van Rooden S; van Osch MJP; Wermer MJH; Terwindt GM; Schreuder FHBM; Klijn CJM; Verbeek MM
    Alzheimers Res Ther; 2023 Jun; 15(1):102. PubMed ID: 37270536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased Cerebrospinal Fluid Amyloid β 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy.
    De Kort AM; Kuiperij HB; Marques TM; Jäkel L; van den Berg E; Kersten I; van Berckel-Smit HEP; Duering M; Stoops E; Abdo WF; Rasing I; Voigt S; Koemans EA; Kaushik K; Warren AD; Greenberg SM; Brinkmalm G; Terwindt GM; Wermer MJH; Schreuder FHBM; Klijn CJM; Verbeek MM
    Ann Neurol; 2023 Jun; 93(6):1173-1186. PubMed ID: 36707720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal Fluid Biomarkers in Dementia Patients with Cerebral Amyloid Angiopathy.
    Li YF; Ge FF; Zhang Y; You H; Zhang ZX
    Chin Med Sci J; 2015 Sep; 30(3):170-3. PubMed ID: 26564416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's disease related biomarkers in bipolar disorder - A longitudinal one-year case-control study.
    Knorr U; Simonsen AH; Jensen CS; Zetterberg H; Blennow K; Akhøj M; Forman J; Hasselbalch SG; Kessing LV
    J Affect Disord; 2022 Jan; 297():623-633. PubMed ID: 34728295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid biomarkers and apolipoprotein E genotype in cerebral amyloid angiopathy. A narrative review.
    Theodorou A; Tsantzali I; Kapaki E; Constantinides VC; Voumvourakis K; Tsivgoulis G; Paraskevas GP
    Cereb Circ Cogn Behav; 2021; 2():100010. PubMed ID: 36324707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer's disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study.
    Motta C; Di Donna MG; Bonomi CG; Assogna M; Chiaravalloti A; Mercuri NB; Koch G; Martorana A
    Alzheimers Res Ther; 2023 Aug; 15(1):144. PubMed ID: 37649105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. β-Amyloid in CSF: Biomarker for preclinical cerebral amyloid angiopathy.
    van Etten ES; Verbeek MM; van der Grond J; Zielman R; van Rooden S; van Zwet EW; van Opstal AM; Haan J; Greenberg SM; van Buchem MA; Wermer MJ; Terwindt GM
    Neurology; 2017 Jan; 88(2):169-176. PubMed ID: 27903811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aβ38 and Aβ43 do not differentiate between Alzheimer's disease and cerebral amyloid angiopathy.
    Dargvainiene J; Jensen-Kondering U; Bender B; Berg D; Brüggemann N; Flüh C; Markewitz R; Neumann A; Röben B; Röcken C; Royl G; Schulte C; Wandinger KP; Weiler C; Margraf NG; Kuhlenbäumer G
    Ann Clin Transl Neurol; 2024 Mar; 11(3):806-811. PubMed ID: 38186185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid Aβ42, t-tau, and p-tau levels in the differential diagnosis of idiopathic normal-pressure hydrocephalus: a systematic review and meta-analysis.
    Chen Z; Liu C; Zhang J; Relkin N; Xing Y; Li Y
    Fluids Barriers CNS; 2017 May; 14(1):13. PubMed ID: 28486988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal Fluid Aβ40 Improves the Interpretation of Aβ42 Concentration for Diagnosing Alzheimer's Disease.
    Dorey A; Perret-Liaudet A; Tholance Y; Fourier A; Quadrio I
    Front Neurol; 2015; 6():247. PubMed ID: 26640457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Amyloid-β, Tau, and α-Synuclein Proteins as Putative Blood Biomarkers in Patients with Cerebral Amyloid Angiopathy.
    Piccarducci R; Caselli MC; Zappelli E; Ulivi L; Daniele S; Siciliano G; Ceravolo R; Mancuso M; Baldacci F; Martini C
    J Alzheimers Dis; 2022; 89(3):1039-1049. PubMed ID: 35964181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative methods for quantifying plasma biomarkers in Alzheimer's disease: Implications for the next frontier in cerebral amyloid angiopathy diagnostics.
    Muir RT; Ismail Z; Black SE; Smith EE
    Alzheimers Dement; 2024 Feb; 20(2):1436-1458. PubMed ID: 37908054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.